Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
With thousands of press releases published each week, it can be difficult to keep up with everything on. To help healthcare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback